Health ❯ Healthcare ❯ Biotechnology

Gene Editing

CRISPR Technology CRISPR Therapeutics AG In Vivo Gene Therapy Clinical Trials Therapies CRISPR Cholesterol Management CRISPR Therapeutics Personalized Medicine Beam Therapeutics

CRISPR Therapeutics’ Pipeline Pitched as Path to One-Time Heart Risk Treatments

Backers see CTX310, CTX320 as single-dose edits that could replace lifelong lipid drugs.

ARK Ramps Up AI Bets With Tempus and WeRide, Cuts Beam and Roku

Aurora Therapeutics Launches to Scale Bespoke Gene Editing for PKU

Contrarius Global Equity Fund Q3 Letter Posts 30.9% Return, Spotlights Media Re‑rating Plays and CRISPR Economics

Regeneron, Tessera Strike $150 Million Gene-Editing Pact for Alpha‑1 Antitrypsin Deficiency

Casgevy Launch Stumbles, Yet Analysts Eye Upside for CRISPR Therapeutics

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion

Next-Generation CAR-T Therapies Deliver Remission in T-Cell Cancers and Extend Survival in Gastric and Brain Tumors

Verve-102 Gene-Editing Therapy Shows Promising LDL Cholesterol Reduction in Early Trial